Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients

Alberto Matteelli; Mario Regazzi; Paola Villani; Giuseppina De Iaco; Maria Cusato; Anna Cristina C Carvalho; Silvio Caligaris; Lina Tomasoni; Maria Manfrin; Susanna Capone; Giampiero Carosi

doi:10.2174/157016207780636588

Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients

Alberto Matteelli, Mario Regazzi, Paola Villani, Giuseppina De Iaco, Maria Cusato, Anna Cristina C Carvalho, Silvio Caligaris, Lina Tomasoni, Maria Manfrin, Susanna Capone, Giampiero Carosi

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (C_trough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.

Original language	English
Pages (from-to)	349-353
Number of pages	5
Journal	Current HIV Research
Volume	5
Issue number	3
DOIs	https://doi.org/10.2174/157016207780636588
Publication status	Published - May 2007

Keywords

Efavirenz
HIV infection
Pharmacokinetic interaction
Rifampicin

ASJC Scopus subject areas

Infectious Diseases

Access to Document

10.2174/157016207780636588

Fingerprint Dive into the research topics of 'Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients'. Together they form a unique fingerprint.

Cite this

Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients. / Matteelli, Alberto; Regazzi, Mario; Villani, Paola; De Iaco, Giuseppina; Cusato, Maria; Carvalho, Anna Cristina C; Caligaris, Silvio; Tomasoni, Lina; Manfrin, Maria; Capone, Susanna; Carosi, Giampiero.

In: Current HIV Research, Vol. 5, No. 3, 05.2007, p. 349-353.

Research output: Contribution to journal › Article › peer-review

Matteelli, Alberto ; Regazzi, Mario ; Villani, Paola ; De Iaco, Giuseppina ; Cusato, Maria ; Carvalho, Anna Cristina C ; Caligaris, Silvio ; Tomasoni, Lina ; Manfrin, Maria ; Capone, Susanna ; Carosi, Giampiero. / Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients. In: Current HIV Research. 2007 ; Vol. 5, No. 3. pp. 349-353.

@article{c5d8def14066452aa18c3d2b3a6d28df,

title = "Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients",

abstract = "Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.",

keywords = "Efavirenz, HIV infection, Pharmacokinetic interaction, Rifampicin",

author = "Alberto Matteelli and Mario Regazzi and Paola Villani and {De Iaco}, Giuseppina and Maria Cusato and Carvalho, {Anna Cristina C} and Silvio Caligaris and Lina Tomasoni and Maria Manfrin and Susanna Capone and Giampiero Carosi",

year = "2007",

month = may,

doi = "10.2174/157016207780636588",

language = "English",

volume = "5",

pages = "349--353",

journal = "Current HIV Research",

issn = "1570-162X",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients

AU - Matteelli, Alberto

AU - Regazzi, Mario

AU - Villani, Paola

AU - De Iaco, Giuseppina

AU - Cusato, Maria

AU - Carvalho, Anna Cristina C

AU - Caligaris, Silvio

AU - Tomasoni, Lina

AU - Manfrin, Maria

AU - Capone, Susanna

AU - Carosi, Giampiero

PY - 2007/5

Y1 - 2007/5

N2 - Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.

AB - Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.

KW - Efavirenz

KW - HIV infection

KW - Pharmacokinetic interaction

KW - Rifampicin

UR - http://www.scopus.com/inward/record.url?scp=34249069242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249069242&partnerID=8YFLogxK

U2 - 10.2174/157016207780636588

DO - 10.2174/157016207780636588

M3 - Article

C2 - 17504177

AN - SCOPUS:34249069242

VL - 5

SP - 349

EP - 353

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 3

ER -